Related Experiment Video
Updated: Jun 6, 2025

Establishment of a Clinic-based Biorepository
Published on: May 29, 2017
PRMT5/WDR77 Enhances the Proliferation of Squamous Cell Carcinoma via the ΔNp63α-p21 Axis
Heng Liang1,2, Matthew L Fisher1, Caizhi Wu1
1Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
Abstract:
Protein arginine methyltransferase 5 (PRMT5) is a critical oncogenic factor in various cancers, and its inhibition has shown promise in suppressing tumor growth. However, the role of PRMT5 in squamous cell carcinoma (SCC) remains largely unexplored. In this study, we analyzed SCC patient data from The Cancer Genome Atlas (TCGA) and the Cancer Dependency Map (DepMap) to investigate the relationship between PRMT5 and SCC proliferation. We employed competition-based cell proliferation assays, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assays, flow cytometry, and in vivo mouse modeling to examine the regulatory roles of PRMT5 and its binding partner WDR77 (WD repeat domain 77). We identified downstream targets, including the p63 isoform ΔNp63α and the cyclin-dependent kinase inhibitor p21, through single-cell RNA-seq, RT-qPCR, and Western blot analyses. Our findings demonstrate that upregulation of PRMT5 and WDR77 correlates with the poor survival of head and neck squamous cell carcinoma (HNSCC) patients. PRMT5/WDR77 regulates the HNSCC-specific transcriptome and facilitates SCC proliferation by promoting cell cycle progression. The PRMT5 and WDR77 stabilize the ΔNp63α Protein, which in turn, inhibits p21. Moreover, depletion of PRMT5 and WDR77 repress SCC in vivo. This study reveals for the first time that PRMT5 and WDR77 synergize to promote SCC proliferation via the ΔNp63α-p21 axis, highlighting a novel therapeutic target for SCC.
Insights
Protein arginine methyltransferase 5 (PRMT5) and WDR77 drive squamous cell carcinoma (SCC) growth by stabilizing ΔNp63α, inhibiting p21. Inhibiting PRMT5 and WDR77 offers a new therapeutic strategy for SCC.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Protein arginine methyltransferase 5 (PRMT5) is implicated in various cancers, but its role in squamous cell carcinoma (SCC) is understudied.
- Understanding PRMT5's function in SCC is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the role of PRMT5 and its binding partner WDR77 in SCC proliferation.
- To identify downstream targets and mechanisms by which PRMT5/WDR77 promotes SCC growth.
Main Methods:
- Analysis of SCC patient data (TCGA, DepMap).
- Cell proliferation assays (competition, MTT), flow cytometry, and in vivo mouse models.
- Molecular analyses including single-cell RNA-seq, RT-qPCR, and Western blot.
Main Results:
- Upregulation of PRMT5 and WDR77 correlates with poor survival in head and neck SCC (HNSCC) patients.
- PRMT5/WDR77 stabilizes the ΔNp63α protein, which inhibits the cell cycle inhibitor p21, promoting SCC proliferation.
- Depletion of PRMT5 and WDR77 suppressed SCC growth in vivo.
Conclusions:
- PRMT5 and WDR77 synergistically promote SCC proliferation through the ΔNp63α-p21 pathway.
- The PRMT5/WDR77 complex represents a novel therapeutic target for SCC treatment.
Related Concept Videos
Abnormal Proliferation
Negative Regulator Molecules
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Canonical Wnt Signaling Pathway
PI3K/mTOR/AKT Signaling Pathway

